What a Sermorelin prescription does and doesn’t tell you
“Is it legit?” sounds like one question, but there’s a lot packed into it. Was there an approved medicine, who makes the preparation now, and what is it meant to help? An old approval answers only the first part. Today’s prescription needs a closer look.
2009
The old approvals ended
Prescribed doesn’t mean FDA-approved
The old approvals ended in June 2009, after the maker asked for them to be withdrawn. They covered a hormone test and treatment for children with growth failure. They don’t approve an adult wellness use today.
A clinician’s prescription is a decision about a person’s care. FDA approval concerns a particular drug product and its evaluated uses. Compounded medicines are not FDA-approved, even when prescribed. Keeping those two decisions separate makes the rest of the conversation much easier to follow.
2013
The later FDA finding
The FDA ruled out a safety withdrawal
In March 2013, the FDA found that the former products hadn’t left sale for safety or effectiveness reasons. That answered an important historical question. It didn’t restore the approvals or assess a compounded preparation made today.
The old product remains in the Orange Book’s discontinued section, part of the FDA’s drug listing. That matters to the ingredient rules below. It doesn’t give a present prescription the old product’s approval, and it can’t tell an adult whether treatment will help.
2025
The compounding rules
There’s a possible route, with conditions attached
The FDA’s March 2025 503B list puts Sermorelin acetate in Category 1, the group it’s evaluating for larger compounding facilities. It also marks the ingredient as a component of an approved drug. The framework for medicines made for individual patients is called 503A. Sermorelin is absent from the May 2026 503A category list.
Under the January 2025 503A guidance, an ingredient in an approved drug can qualify without appearing on its list of compounding ingredients. That may offer a route to making Sermorelin acetate for a named patient, if every other condition is met. This is an interpretation of the general rules, rather than a Sermorelin-specific FDA statement. It can’t certify a particular preparation’s legality.
What is useful to check now?
The person, purpose and preparation all matter. A consultation can end without a prescription. State rules matter too: telehealth licensing depends on where the patient is located, so an online service isn’t automatically available everywhere.
A physician’s licence can be checked through the state medical board. A pharmacy has a separate state board of pharmacy. Those checks establish licensing, rather than a likely treatment result. Earlier work reported flushing and injection-site pain; the safety page explains why it can’t settle long-term adult risk.